title: Deal watch: MSD buys in to emerging epigenetic cancer target.
authors.forename: Megan
authors.initials: M
authors.lastname: Cully
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends*; D004345:Drug Industry / Q000379:methods / Q000639:trends*; D057890:Epigenomics / Q000379:methods / Q000639:trends*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D011484:Protein-Arginine N-Methyltransferases / Q000037:antagonists & inhibitors / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; C400529:PRMT5 protein, human; D011484:Protein-Arginine N-Methyltransferases